Unknown

Dataset Information

0

The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma.


ABSTRACT: Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumour in humans and is highly resistant to current treatment modalities. We have explored the combined treatment of the endoplasmic reticulum (ER) stress-inducing agent 2,5-dimethyl-celecoxib (DMC) and TNF-related apoptosis-inducing ligand (TRAIL WT) or the DR5-specific TRAIL D269H/E195R variant as a potential new strategy to eradicate GBM cells using TRAIL-resistant and -sensitive GBM cells. GBM cell lines were investigated for their sensitivity to TRAIL, DMC and combination of both agents. Cell viability was measured by MTS assay and apoptosis was assessed by Annexin V/PI and acridine orange staining. Caspase activation and protein expression levels were analysed with Western blotting. Death Receptor (DR) cell surface expression levels were quantified by flow cytometry. DR5 expression was increased in U87 cells by ectopic expression using a retroviral plasmid and survivin expression was silenced using specific siRNAs. We demonstrate that A172 expresses mainly DR5 on the cell surface and that these cells show increased sensitivity for the DR5-specific rhTRAIL D269H/E195R variant. In contrast, U87 cells show low DR cell surface levels and is insensitive via both DR4 and DR5. We determined that DMC treatment displays a dose-dependent reduction in cell viability against a number of GBM cells, associated with ER stress induction, as shown by the up-regulation of glucose-regulated protein 78 (GRP78) and CCAAT/-enhancer-binding protein homologous protein (CHOP) in A172 and U87 cells. The dramatic decrease in cell viability is not accompanied by a correspondent increase in Annexin V/PI or caspase activation typically seen in apoptotic or/and necrotic cells within 24h of treatment. Although DMC did not affect DR5 expression in the GBM cells, it increased TRAIL-induced caspase-8 activation in both TRAIL-sensitive and -resistant cells, indicating that DMC potentiates initiator caspase activation in these cells. In A172 cells, sub-toxic concentrations of DMC greatly potentiated TRAIL-induced apoptosis. Furthermore, DMC strongly reduced survivin expression in A172 and U87 cells and silencing of this anti-apoptotic protein partially sensitized cells to TRAIL-induced apoptosis. Our findings corroborate that DMC is a promising agent against GBM, and uncovers a potential synergistic cooperation with TRAIL in this highly malignant cancer.

SUBMITTER: van Roosmalen IAM 

PROVIDER: S-EPMC4554544 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma.

van Roosmalen Ingrid A M IAM   Reis Carlos R CR   Setroikromo Rita R   Yuvaraj Saravanan S   Joseph Justin V JV   Tepper Pieter G PG   Kruyt Frank A E FAE   Quax Wim J WJ  

SpringerPlus 20140901


Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumour in humans and is highly resistant to current treatment modalities. We have explored the combined treatment of the endoplasmic reticulum (ER) stress-inducing agent 2,5-dimethyl-celecoxib (DMC) and TNF-related apoptosis-inducing ligand (TRAIL WT) or the DR5-specific TRAIL D269H/E195R variant as a potential new strategy to eradicate GBM cells using TRAIL-resistant and -sensitive GBM cells. GBM cell lines were investigated f  ...[more]

Similar Datasets

| S-EPMC5354785 | biostudies-literature
| S-EPMC4250062 | biostudies-literature
| S-EPMC2174520 | biostudies-other
| S-EPMC3938842 | biostudies-other
| S-EPMC7077595 | biostudies-literature
| S-EPMC4038578 | biostudies-literature
| S-EPMC5341238 | biostudies-literature
| S-EPMC3151668 | biostudies-literature
| S-EPMC5502302 | biostudies-literature
| S-EPMC3944242 | biostudies-literature